Laboratory testing of anticoagulants: the present and the future

Summary This review provides an update on laboratory testing and monitoring for existing and emerging anticoagulants, starting with an overview of haemostasis and the routine coagulation tests currently employed within most haemostasis laboratories, including the prothrombin time (PT)/international normalised ratio (INR) and the activated partial thromboplastin time (APTT). Current anticoagulant therapy and laboratory monitoring is then discussed in terms of benefits and limitations, followed by a similar brief discussion of the new and emerging anticoagulants. The main focus, however, is laboratory testing related to vitamin K antagonists, heparin, lepirudin and the new agents dabigatran etexilate and rivaroxaban. Although the newer agents do not require laboratory monitoring, laboratory testing will occasionally be required, and pathology laboratories should become proactive in developing appropriate strategies. The tests most likely to fulfill this role are the ecarin clotting time (or chromogenic alternatives), and the chromogenic anti-Xa assay. Nevertheless, the dilute Russell viper venom time (dRVVT) assay may provide another alternative, and existing routine tests are also likely to be utilised for the foreseeable future, potentially also for laboratory testing of the new anticoagulants, albeit perhaps in modified form.

[1]  A. Lazo-Langner,et al.  New oral anticoagulants , 2013, Canadian Medical Association Journal.

[2]  M. Samama,et al.  Laboratory assessment of new anticoagulants , 2011, Clinical chemistry and laboratory medicine.

[3]  G. Lippi,et al.  Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? , 2011, Clinical chemistry and laboratory medicine.

[4]  M. Franchini,et al.  Preventing postsurgical venous thromboembolism: pharmacological approaches. , 2011, Seminars in thrombosis and hemostasis.

[5]  L. Joutsi-Korhonen,et al.  Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. , 2011, Seminars in thrombosis and hemostasis.

[6]  C. Kessler,et al.  Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. , 2011, Seminars in thrombosis and hemostasis.

[7]  T. Lindahl,et al.  Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays , 2010, Thrombosis and Haemostasis.

[8]  E. Favaloro,et al.  Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays , 2011, Clinical chemistry and laboratory medicine.

[9]  G. Lippi,et al.  Coagulation update: what's new in hemostasis testing? , 2011, Thrombosis research.

[10]  J. Ansell.  Warfarin versus new agents: interpreting the data. , 2010, Hematology. American Society of Hematology. Education Program.

[11]  N. Key,et al.  Novel Oral Anticoagulants: Implications in the Perioperative Setting , 2010, Anesthesiology.

[12]  E. Favaloro,et al.  Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box? , 2010, Clinical chemistry and laboratory medicine.

[13]  G. Lippi,et al.  Shortened activated partial thromboplastin time: causes and management , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  G. Lippi,et al.  Laboratory testing in pharmacies , 2010, Clinical chemistry and laboratory medicine.

[15]  L. Joutsi-Korhonen,et al.  Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. , 2010, Thrombosis research.

[16]  E. Favaloro.  Laboratory testing in disseminated intravascular coagulation. , 2010, Seminars in thrombosis and hemostasis.

[17]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[18]  E. Favaloro,et al.  A laboratory evaluation into the short activated partial thromboplastin time , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  Elisabeth Perzborn,et al.  Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor , 2010, Thrombosis and Haemostasis.

[20]  J. Beilby,et al.  Assessing agreement between point of care and pathology laboratory results for INR: experiences from the Point of Care Testing in General Practice Trial , 2010, Pathology.

[21]  K. W. Phillips,et al.  The clinical implications of new oral anticoagulants: Will the potential advantages be achieved? , 2009, Thrombosis and Haemostasis.

[22]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  G. Di Minno,et al.  Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism , 2009, Seminars in thrombosis and hemostasis.

[24]  Giuseppe Lippi,et al.  Laboratory investigation of thrombophilia: the good, the bad, and the ugly. , 2009, Seminars in thrombosis and hemostasis.

[25]  G. Lippi,et al.  The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. , 2009, Seminars in thrombosis and hemostasis.

[26]  F. Hobbs,et al.  Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. , 2009, Seminars in thrombosis and hemostasis.

[27]  M. O’Donnell,et al.  New anticoagulants for atrial fibrillation. , 2009, Seminars in thrombosis and hemostasis.

[28]  Giuseppe Lippi,et al.  Pharmacogenetics of vitamin K antagonists: useful or hype? , 2009, Clinical chemistry and laboratory medicine.

[29]  H. Büller,et al.  Hemostatic abnormalities and arterial thrombosis. , 2009, Seminars in thrombosis and hemostasis.

[30]  G. Lippi,et al.  Milestones and perspectives in coagulation and hemostasis. , 2009, Seminars in thrombosis and hemostasis.

[31]  A. Tripodi,et al.  Laboratory monitoring of anticoagulation: where do we stand? , 2009, Seminars in thrombosis and hemostasis.

[32]  E. Grifoni,et al.  The role of D-dimer testing in patients with suspected venous thromboembolism. , 2009, Seminars in thrombosis and hemostasis.

[33]  Murray Adams,et al.  Assessment of thrombin generation: useful or hype? , 2009, Seminars in thrombosis and hemostasis.

[34]  L. Baudhuin,et al.  Pharmacogenetics in hemostasis: friend or foe? , 2009, Seminars in thrombosis and hemostasis.

[35]  D. Cines,et al.  Interlaboratory agreement in the monitoring of unfractionated heparin using the anti‐factor Xa‐correlated activated partial thromboplastin time , 2009, Journal of thrombosis and haemostasis : JTH.

[36]  G. Lippi,et al.  Pathogenesis of venous thromboembolism: when the cup runneth over. , 2008, Seminars in thrombosis and hemostasis.

[37]  G. Lippi,et al.  Activated Partial Thromboplastin Time: New Tricks for an Old Dogma , 2008, Seminars in thrombosis and hemostasis.

[38]  S. Kitchen,et al.  Quality assessment in point-of-care coagulation testing. , 2008, Seminars in thrombosis and hemostasis.

[39]  E. Favaloro,et al.  Standardization of the INR: how good is your laboratory's INR and can it be improved? , 2008, Seminars in thrombosis and hemostasis.

[40]  A. Tripodi.  The history of phenotypic testing in thrombosis and hemostasis. , 2008, Seminars in thrombosis and hemostasis.

[41]  M. Makris,et al.  Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro , 2008, Thrombosis and Haemostasis.

[42]  D. Hoppensteadt,et al.  Survival of heparins, oral anticoagulants, and aspirin after the year 2010. , 2008, Seminars in thrombosis and hemostasis.

[43]  Martin Wehling,et al.  Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa , 2008, Seminars in thrombosis and hemostasis.

[44]  G. Lippi,et al.  Help me, Doctor! My D-dimer is raised , 2008, Annals of medicine.

[45]  C. Richards,et al.  Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.

[46]  A. Street,et al.  How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. , 2005, Laboratory hematology : official publication of the International Society for Laboratory Hematology.

[47]  A. Street,et al.  An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin , 2005, Pathology.

[48]  G. Nowak.  The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors , 2003, Pathophysiology of Haemostasis and Thrombosis.

[49]  Lu Hk.  Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. , 2000 .

[50]  H. Lui.  Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. , 2000, The Journal of invasive cardiology.

[51]  G. Lippi,et al.  Evaluation of the Activated Partial Thrombo-plastin Time (APTT) Sensitivity to Heparin Using Five Commercial Reagents: Implications for Therapeutic Monitoring , 1998, Clinical chemistry and laboratory medicine.